Accumetrics Signs Partnership Agreement With Grifols

Accumetrics has signed a new exclusive agreement with Grifols for the distribution of its VerifyNow in Spain, Portugal and Chile.

The VerifyNow assesses response to life-saving antiplatelet therapies, such as aspirin, Plavix, Effient and GP IIb/IIIa inhibitors. Patients respond to antiplatelet medications differently and these tests help physicians ensure that their patients are receiving the optimal treatment.

Timothy Still, president and CEO of Accumetrics, said: We’re extremely excited to see distribution of our VerifyNow reach Spain, Portugal and Chile. We have chosen Grifols as our exclusive partner. This partnership continues to emphasize our focus on expanding our global distribution channels, and supports our vision to provide physicians access to critical information for managing their cardiovascular patients on antiplatelet therapies.